News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Tom Powles: Podcast with Neal Shore around the CREST RIII untreated NMIBC BCG +/- PD1 trial
Tom Powles and Neal Shore
Apr 29, 2025, 10:50

Tom Powles: Podcast with Neal Shore around the CREST RIII untreated NMIBC BCG +/- PD1 trial

Tom Powles, Professor at the University of London, shared a post on X:

“Here is a podcast with Neal Shore around the CREST RIII untreated NMIBC BCG +/- PD1 trial which show and EFS advantage but with expected immune related toxicity.

Here we discuss the highlights and risk benefit ratio.”

Tom Powles: Podcast with Neal Shore around the CREST RIII untreated NMIBC BCG +/- PD1 trial

More posts featuring Tom Powles.

cancer CREST RIII fight against cancer Global fight against cancer Neal Shore NMIBC BCG + OncoDaily Oncology PD1 trial Tom Powles University of London
Special Coverage
Societies
Sep 5, 2025, 03:27
Europe’s Progress on the Early Detection of Prostate Cancer - European Cancer Organization
Voices
Sep 5, 2025, 03:11
Sumanta Pal: What Role Does Metabolism Play in Cancer Progression and Treatment?
Voices
Sep 5, 2025, 03:08
Polikalipo Kagina: Strengthening Radiotherapy Awareness and Support
Insight
Sep 5, 2025, 03:04
Luca Boldrini: A New Era in Radiation Oncology
Voices
Sep 5, 2025, 02:17
Advancing Pediatric Leukemia Research in 2025 - St. Jude Children's Research Hospital
Voices
Sep 4, 2025, 23:59
Roberto Borea: Selected Liquid Biopsy Abstracts for WCLC25
Insight
Sep 4, 2025, 20:03
Aruni Ghose: AI-Enhanced Medical Imaging for Cancer Diagnosis
Insight
Sep 4, 2025, 19:35
A Reminder That Education Is Essential to Patient Care - Elekta
Dialogues
Sep 4, 2025, 18:19
MASCC 2025 Presidential Training Fellowship Spotlight: Dr. Colleen Ann Cuthbert
Immune Oncology
Sep 4, 2025, 16:49
LIBRETTO-431 East Asia Subgroup Results of First-line Selpercatinib vs Chemotherapy + Pembrolizumab in RET Fusion–Positive NSCLC
OncoDaily Pulse
Sep 4, 2025, 16:17
Mariam Sargsyan: Meet the Experts of VIRO 2025
Voices
Sep 4, 2025, 15:59
Markus Kosch: Finding Strength After Diagnosis - A Conversation with Claudia Poguntke